Morning Overview on MSN
Experimental prostate cancer drug shrinks tumors in early clinical trial
Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...
Investigators expanded on previous results from the DEAR study, comparing darolutamide versus enzalutamide and apalutamide ...
The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
6hon MSN
Pfizer Inc. (PFE) Announces Positive Topline Results From Phase 3 TALAPRO-3 Study of TALZENNA®
Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks under $50 to invest in now. Pfizer Inc. (NYSE:PFE) announced on ...
A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...
MedPage Today on MSN
Estradiol patch matches LHRH agonists for locally advanced prostate cancer
Similar 3-year metastasis-free survival, fewer hot flashes, more gynecomastia ...
This figure shows the structure of PTGES3. The research team made the association after creating a fluorescent tag that tracks androgen receptor levels in real time. The androgen receptor is a hormone ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results